Radiotherapy with genomic-adjusted radiation dose
- PMID: 34735810
- DOI: 10.1016/S1470-2045(21)00541-6
Radiotherapy with genomic-adjusted radiation dose
Conflict of interest statement
TK reports payment for lectures from AstraZeneca, outside the submitted work. KK declares no competing interests. We would like to thank Editage (www.editage.jp) for English language editing services.
Comment in
-
Radiotherapy with genomic-adjusted radiation dose.Lancet Oncol. 2021 Nov;22(11):e469. doi: 10.1016/S1470-2045(21)00583-0. Lancet Oncol. 2021. PMID: 34735811 No abstract available.
-
Radiotherapy with genomic-adjusted radiation dose - Authors' reply.Lancet Oncol. 2021 Nov;22(11):e470-e471. doi: 10.1016/S1470-2045(21)00601-X. Lancet Oncol. 2021. PMID: 34735812 No abstract available.
Comment on
-
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.Lancet Oncol. 2021 Sep;22(9):1221-1229. doi: 10.1016/S1470-2045(21)00347-8. Epub 2021 Aug 4. Lancet Oncol. 2021. PMID: 34363761
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
